Please login to the form below

Not currently logged in
Email:
Password:

G-BA

This page shows the latest G-BA news and features for those working in and with pharma, biotech and healthcare.

UK, Germany back routine use of J&J’s Tremfya

UK, Germany back routine use of J&J’s Tremfya

The National Institute for Health and Care Excellence (NICE) for England and Wales, the Scottish Medicines Consortium (SMC) and Germany’s Federal Joint Committee (G-BA) are the first health technology ... Meanwhile the G-BA has published its decision

Latest news

More from news
Approximately 5 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • The price is right? The price is right?

    The company is obliged to submit an application for the assessment of potential additional benefit, providing the G-BA with a value dossier to be evaluated by IQWiG. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    PME that it currently has no other commissions from the G-BA to assess other biologic products.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). ... A key step is a positive assessment by the G-BA of a drug's added benefit relative to

  • Oncology drugs under AMNOG: part one Oncology drugs under AMNOG: part one

    Instead, they are reimbursed at the manufacturer's price only during the first year on the market, while the Federal Joint Committee (G-BA) assesses the new product or indication for ... The G-BA also rules on the strength of evidence of the added benefit

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    IQWiG's recommendation is not final, however, and once an evidence report is create, it is then passed to a public legal entity called the Federal Joint Committee (G-BA). ... There is a hearing at G-BA in which criticism can be discussed,” she says.

More from intelligence
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    The G-BA also rules on the strength of evidence of the added benefit. ... explore other options to better address the likely requirements of the G-BA.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics